Trial Profile
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary) ; Mycophenolate mofetil
- Indications Interstitial lung diseases; Systemic scleroderma
- Focus Therapeutic Use
- Acronyms SLSIII
- 22 Feb 2023 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
- 15 Nov 2021 Planned primary completion date changed from 15 Apr 2022 to 1 Apr 2022.